JP2024509818A5 - - Google Patents
Info
- Publication number
- JP2024509818A5 JP2024509818A5 JP2023553045A JP2023553045A JP2024509818A5 JP 2024509818 A5 JP2024509818 A5 JP 2024509818A5 JP 2023553045 A JP2023553045 A JP 2023553045A JP 2023553045 A JP2023553045 A JP 2023553045A JP 2024509818 A5 JP2024509818 A5 JP 2024509818A5
- Authority
- JP
- Japan
- Prior art keywords
- section
- compound
- compound according
- item
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025036310A JP7797723B2 (ja) | 2021-03-10 | 2025-03-07 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025088466A JP7731021B1 (ja) | 2021-03-10 | 2025-05-28 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025135673A JP2026000898A (ja) | 2021-03-10 | 2025-08-18 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159271P | 2021-03-10 | 2021-03-10 | |
| US63/159,271 | 2021-03-10 | ||
| US202163226551P | 2021-07-28 | 2021-07-28 | |
| US63/226,551 | 2021-07-28 | ||
| US202163234487P | 2021-08-18 | 2021-08-18 | |
| US63/234,487 | 2021-08-18 | ||
| US202163292815P | 2021-12-22 | 2021-12-22 | |
| US63/292,815 | 2021-12-22 | ||
| US202263308790P | 2022-02-10 | 2022-02-10 | |
| US63/308,790 | 2022-02-10 | ||
| PCT/US2022/019513 WO2022192370A1 (en) | 2021-03-10 | 2022-03-09 | Small molecule inhibitors of mammalian slc6a19 function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036310A Division JP7797723B2 (ja) | 2021-03-10 | 2025-03-07 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509818A JP2024509818A (ja) | 2024-03-05 |
| JP2024509818A5 true JP2024509818A5 (enExample) | 2025-02-19 |
| JP7649386B2 JP7649386B2 (ja) | 2025-03-19 |
Family
ID=83227044
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553045A Active JP7649386B2 (ja) | 2021-03-10 | 2022-03-09 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025036310A Active JP7797723B2 (ja) | 2021-03-10 | 2025-03-07 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025088466A Active JP7731021B1 (ja) | 2021-03-10 | 2025-05-28 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025135673A Pending JP2026000898A (ja) | 2021-03-10 | 2025-08-18 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036310A Active JP7797723B2 (ja) | 2021-03-10 | 2025-03-07 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025088466A Active JP7731021B1 (ja) | 2021-03-10 | 2025-05-28 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
| JP2025135673A Pending JP2026000898A (ja) | 2021-03-10 | 2025-08-18 | 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20240208923A1 (enExample) |
| EP (1) | EP4304586A4 (enExample) |
| JP (4) | JP7649386B2 (enExample) |
| KR (1) | KR20230162935A (enExample) |
| AU (1) | AU2022234302A1 (enExample) |
| CA (1) | CA3209914A1 (enExample) |
| CL (2) | CL2023002581A1 (enExample) |
| CO (1) | CO2023013218A2 (enExample) |
| CR (1) | CR20230467A (enExample) |
| DO (2) | DOP2023000178A (enExample) |
| EC (1) | ECSP23075523A (enExample) |
| IL (1) | IL305262A (enExample) |
| MX (1) | MX2023010467A (enExample) |
| PE (2) | PE20260125A1 (enExample) |
| PY (1) | PY2216888A (enExample) |
| TN (1) | TN2023000216A1 (enExample) |
| TW (1) | TWI921490B (enExample) |
| UY (1) | UY39667A (enExample) |
| WO (1) | WO2022192370A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL305262A (en) | 2021-03-10 | 2023-10-01 | Jnana Therapeutics Inc | Small molecule inhibitors of mammalian SLC6A19 function |
| HUE070709T2 (hu) | 2021-08-18 | 2025-06-28 | Nurix Therapeutics Inc | Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk |
| US20250084054A1 (en) * | 2021-12-22 | 2025-03-13 | Janna Therapeutics Inc | Small molecule inhibitors of mammalian slc6a19 function |
| KR20240154642A (ko) | 2022-02-28 | 2024-10-25 | 아지오스 파마슈티컬스 아이엔씨. | 페닐알라닌 하이드록실라아제 돌연변이의 안정화에 유용한 화합물 및 방법 |
| EP4554584A4 (en) * | 2022-07-14 | 2026-07-15 | Jnana Therapeutics Inc | SMALL MOLECULES THAT INHIBIT SLC6A19 FUNCTION IN A MAMMAL |
| CA3267536A1 (en) * | 2022-09-14 | 2024-03-21 | Jnana Therapeutics Inc. | DOSING REGIMEN FOR THE TREATMENT OF PKU WITH A PIPERIDINE INHIBITOR OF THE SLC6A19 FUNCTION |
| EP4622960A1 (en) * | 2022-11-22 | 2025-10-01 | Maze Therapeutics, Inc. | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof |
| EP4626420A1 (en) * | 2022-11-30 | 2025-10-08 | Jnana Therapeutics Inc. | Crystalline forms of a piperidine inhibitor of slc6a19 function |
| CN121487736A (zh) * | 2023-06-14 | 2026-02-06 | 杰那医疗公司 | Slc6a19功能的哌啶抑制剂 |
| CN121399098A (zh) | 2023-06-30 | 2026-01-23 | 赛诺菲 | 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法 |
| KR20260049549A (ko) * | 2023-08-11 | 2026-04-14 | 제이나나 테라퓨틱스 인코포레이티드 | Slc6a19 기능의 바이사이클릭 헤테로아릴 함유 피페리딘 억제제 |
| TW202515556A (zh) * | 2023-08-17 | 2025-04-16 | 美商杰那醫療公司 | Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑 |
| WO2025049658A1 (en) * | 2023-08-30 | 2025-03-06 | Agios Pharmaceuticals, Inc. | 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine derivatives as mutant pah protein stabilizers for the treatment of phenylketonuria |
| WO2025214397A1 (zh) * | 2024-04-10 | 2025-10-16 | 长春金赛药业有限责任公司 | Slc6a19抑制剂化合物、药物组合物及其制备方法和应用 |
| US20250346567A1 (en) * | 2024-05-13 | 2025-11-13 | Pfizer Inc. | Substituted pyridine and phenyl compounds |
| US12630562B2 (en) | 2024-08-07 | 2026-05-19 | Arcus Biosciences, Inc. | Piperidylurea compounds and methods of use thereof |
| WO2026038155A1 (en) * | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Substituted pyridine compounds |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750348B1 (en) | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| FR2793248B1 (fr) | 1999-05-03 | 2001-06-29 | Adir | Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6500844B1 (en) | 1999-06-11 | 2002-12-31 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| MXPA03002263A (es) * | 2000-09-14 | 2003-06-24 | Schering Corp | Antagonistas de receptor de neuropeptido y y5 de urea sustituidos. |
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| US20050043545A1 (en) | 2001-11-02 | 2005-02-24 | Gianpalol Bravi | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| WO2003093436A2 (en) | 2002-04-30 | 2003-11-13 | University Of Florida | Treatment for phenylketonuria |
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| JP2009507855A (ja) * | 2005-09-08 | 2009-02-26 | スミスクライン・ビーチャム・コーポレイション | 非環式１，４−ジアミンおよびその使用 |
| WO2007115232A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010521456A (ja) | 2007-03-13 | 2010-06-24 | アレテ セラピューティクス， インコーポレイテッド | 可溶性エポキシドヒドロラーゼ阻害剤 |
| JP2010180177A (ja) * | 2009-02-06 | 2010-08-19 | Dainippon Sumitomo Pharma Co Ltd | 環状アミノピラゾールアミド誘導体 |
| FR2944206B1 (fr) | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
| WO2011060396A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Aliphatic amines based heterocycles useful as hiv entry blockers |
| WO2011060397A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Substituted amino heterocycles useful as hiv antagonists |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| IN2014DN10328A (enExample) | 2012-06-20 | 2015-08-07 | Sandoz Ag | |
| BR112015023922A2 (pt) * | 2013-03-15 | 2017-07-18 | Als Mountain Llc | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes |
| AU2014287209B2 (en) * | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| TWI690512B (zh) | 2014-03-07 | 2020-04-11 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
| WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| WO2018112136A1 (en) * | 2016-12-15 | 2018-06-21 | Ariad Pharmaceuticals, Inc. | Aminothiazole compounds as c-kit inhibitors |
| WO2019040106A2 (en) * | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES |
| WO2019046303A1 (en) * | 2017-08-28 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | METHOD FOR PREDICTING PATIENT RESPONSE TO SLC MODULATOR PROCESSING |
| TWI834637B (zh) | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
| GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
| US12698259B2 (en) | 2018-10-15 | 2026-08-04 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof |
| CN111978311B (zh) | 2019-05-21 | 2024-05-31 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| CN114269719A (zh) | 2019-06-28 | 2022-04-01 | Rti国际 | 作为cb1变构调节剂的脲衍生物 |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| AU2022212469B2 (en) | 2021-01-27 | 2026-04-30 | Intervet International B.V. | Antiparasitic compounds |
| IL305752A (en) | 2021-03-10 | 2023-11-01 | Dice Molecules Sv Inc | INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES |
| IL305262A (en) * | 2021-03-10 | 2023-10-01 | Jnana Therapeutics Inc | Small molecule inhibitors of mammalian SLC6A19 function |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2023283213A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
| TW202321229A (zh) | 2021-08-18 | 2023-06-01 | 美商富曼西公司 | 殺真菌的取代的雜環化合物 |
| HUE070709T2 (hu) | 2021-08-18 | 2025-06-28 | Nurix Therapeutics Inc | Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk |
| IL310368A (en) | 2021-08-18 | 2024-03-01 | Chemocentryx Inc | Arylsulfonyl(hydroxy)piperidines as CCR6 inhibitors |
| TW202325288A (zh) | 2021-11-05 | 2023-07-01 | 英商喜翠克斯治療有限公司 | 新穎化合物 |
| CA3241713A1 (en) | 2021-12-22 | 2023-06-29 | Irene BASSANETTI | Triazolone derivative salt as neutrophil elastase inhibitor |
| AU2022418385A1 (en) | 2021-12-22 | 2024-05-30 | Sitryx Therapeutics Limited | Phthalazine derivatives as pyruvate kinase modulators |
| WO2023122140A1 (en) | 2021-12-22 | 2023-06-29 | Synnovation Therapeutics, Inc. | Parp1 inhibitors |
| CR20240297A (es) | 2021-12-22 | 2024-09-18 | Incyte Corp | Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación |
| US20250084054A1 (en) | 2021-12-22 | 2025-03-13 | Janna Therapeutics Inc | Small molecule inhibitors of mammalian slc6a19 function |
| US12030866B2 (en) | 2021-12-23 | 2024-07-09 | Springworks Therapeutics, Inc. | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD |
| CN120076801A (zh) | 2022-07-14 | 2025-05-30 | 杰那医疗公司 | 哺乳动物slc6a19功能的小分子抑制剂 |
| EP4554584A4 (en) | 2022-07-14 | 2026-07-15 | Jnana Therapeutics Inc | SMALL MOLECULES THAT INHIBIT SLC6A19 FUNCTION IN A MAMMAL |
| JP2025531154A (ja) | 2022-09-14 | 2025-09-19 | ジュニャーナ セラピューティクス インコーポレイテッド | 哺乳類ｓｌｃ６ａ１９機能のコレクターを用いるｐｋｕの処置 |
| EP4587022A1 (en) | 2022-09-14 | 2025-07-23 | Jnana Therapeutics Inc. | Treating pku with spiro-substituted and other piperidine inhibitors of slc6a19 function |
| CA3267536A1 (en) | 2022-09-14 | 2024-03-21 | Jnana Therapeutics Inc. | DOSING REGIMEN FOR THE TREATMENT OF PKU WITH A PIPERIDINE INHIBITOR OF THE SLC6A19 FUNCTION |
| EP4622960A1 (en) | 2022-11-22 | 2025-10-01 | Maze Therapeutics, Inc. | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof |
| EP4626420A1 (en) | 2022-11-30 | 2025-10-08 | Jnana Therapeutics Inc. | Crystalline forms of a piperidine inhibitor of slc6a19 function |
| CN121487736A (zh) | 2023-06-14 | 2026-02-06 | 杰那医疗公司 | Slc6a19功能的哌啶抑制剂 |
| KR20260049549A (ko) | 2023-08-11 | 2026-04-14 | 제이나나 테라퓨틱스 인코포레이티드 | Slc6a19 기능의 바이사이클릭 헤테로아릴 함유 피페리딘 억제제 |
| TW202515556A (zh) | 2023-08-17 | 2025-04-16 | 美商杰那醫療公司 | Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑 |
-
2022
- 2022-03-09 IL IL305262A patent/IL305262A/en unknown
- 2022-03-09 AU AU2022234302A patent/AU2022234302A1/en active Pending
- 2022-03-09 PE PE2025002437A patent/PE20260125A1/es unknown
- 2022-03-09 TN TNP/2023/000216A patent/TN2023000216A1/en unknown
- 2022-03-09 WO PCT/US2022/019513 patent/WO2022192370A1/en not_active Ceased
- 2022-03-09 KR KR1020237032431A patent/KR20230162935A/ko active Pending
- 2022-03-09 MX MX2023010467A patent/MX2023010467A/es unknown
- 2022-03-09 PE PE2023002500A patent/PE20231987A1/es unknown
- 2022-03-09 EP EP22767877.8A patent/EP4304586A4/en active Pending
- 2022-03-09 CA CA3209914A patent/CA3209914A1/en active Pending
- 2022-03-09 US US18/281,138 patent/US20240208923A1/en active Pending
- 2022-03-09 JP JP2023553045A patent/JP7649386B2/ja active Active
- 2022-03-09 CR CR20230467A patent/CR20230467A/es unknown
- 2022-03-10 UY UY0001039667A patent/UY39667A/es unknown
- 2022-03-10 TW TW111108813A patent/TWI921490B/zh active
- 2022-03-10 PY PY202202216888A patent/PY2216888A/es unknown
-
2023
- 2023-08-31 CL CL2023002581A patent/CL2023002581A1/es unknown
- 2023-09-04 DO DO2023000178A patent/DOP2023000178A/es unknown
- 2023-10-03 CO CONC2023/0013218A patent/CO2023013218A2/es unknown
- 2023-10-05 EC ECSENADI202375523A patent/ECSP23075523A/es unknown
-
2024
- 2024-12-11 US US18/977,370 patent/US12319668B2/en active Active
-
2025
- 2025-03-07 JP JP2025036310A patent/JP7797723B2/ja active Active
- 2025-05-09 US US19/203,913 patent/US20260001859A1/en active Pending
- 2025-05-28 JP JP2025088466A patent/JP7731021B1/ja active Active
- 2025-05-30 US US19/224,208 patent/US12703692B2/en active Active
- 2025-05-30 US US19/224,188 patent/US12595244B2/en active Active
- 2025-08-18 JP JP2025135673A patent/JP2026000898A/ja active Pending
-
2026
- 2026-02-18 CL CL2026000479A patent/CL2026000479A1/es unknown
- 2026-03-31 DO DO2026000093A patent/DOP2026000093A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6907173B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP6506836B2 (ja) | Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン | |
| JP2021534124A5 (enExample) | ||
| JP2021511360A5 (enExample) | ||
| JP2025510074A5 (enExample) | ||
| JP7710215B2 (ja) | ピロール化合物 | |
| JP2025500308A5 (enExample) | ||
| JP2023521351A5 (enExample) | ||
| JP2007504160A5 (enExample) | ||
| JP2005514420A5 (enExample) | ||
| JP2023543254A5 (enExample) | ||
| JP2024507139A5 (enExample) | ||
| JP2021533206A5 (enExample) | ||
| CA2547347A1 (en) | Diazaindole-dicarbonyl-piperazinyl antiviral agents | |
| JP2022526450A (ja) | Ｃｄ４０－ｃｄ１５４結合の阻害剤 | |
| JP2024509760A5 (enExample) | ||
| FI4225753T3 (fi) | Voimakkaita ja selektiivisiä yhdisteitä serotoniini 1b -reseptorin modulaattoreina | |
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JP2024538602A5 (enExample) | ||
| JP6484168B2 (ja) | 抗ウイルス活性を有するメタンチオン化合物 | |
| JP2021523178A5 (enExample) | ||
| JP2025515002A5 (enExample) | ||
| CA2630040A1 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| JPS5840552B2 (ja) | １，４− ベンゾジオキサンノ アミンユウドウタイノセイホウ | |
| JP2008516914A5 (enExample) |